Esophageal squamous cell carcinoma is one of the most frequent causes of cancer death worldwide and effective diagnosis is needed.
Dr Yi-Wei Zu and colleagues from China assessed the diagnostic potential of an autoantibody panel that may benefit early diagnosis.
The research team analyzed data for patients with esophageal squamous cell carcinoma and normal controls in a test cohort and a validation cohort.
Autoantibody levels were measured against a panel of 6 tumor-associated antigens (p53, NY-ESO-1, matrix metalloproteinase-7 (MMP-7), heat shock protein 70 (Hsp70), peroxiredoxin VI (Prx VI), and BMI1 polycomb ring finger oncogene (Bmi-1)) by enzyme-linked immunosorbent assay.
The team assessed serum autoantibodies in 513 participants, including 388 with esophageal squamous cell carcinoma and 125 normal controls.
|Autoantibodies to at least 1 of 6 antigens demonstrated a sensitivity of 57%|
|American Journal of Gastroenterology|
The validation cohort comprised 371 participants, of which 237 had esophageal squamous cell carcinoma, and 134 were normal controls.
Autoantibodies to at least 1 of 6 antigens demonstrated a sensitivity/specificity of 57%, and 51% in the test and validation cohorts, respectively.
Measurement of the autoantibody panel could differentiate early-stage esophageal squamous cell carcinoma patients from normal controls in the test cohort.
In either cohort, the team observed no significant differences when patients were subdivided by age, gender, smoking status, size of tumor, site of tumor, depth of tumor invasion, histological grade, lymph node status, TNM stage, or early-stage and late-stage groups.
Dr Xu's team concludes, "Measurement of an autoantibody response to multiple tumor-associated antigens in an optimized panel assay, to help discriminate early-stage esophageal squamous cell carcinoma patients from normal controls, may aid in early detection of esophageal squamous cell carcinoma."